Results 201 to 210 of about 2,390,694 (316)

Alternative Therapies and Medical Science: Designing Clinical Trials of Alternative/Complementary Medicines—Is Evidence‐Based Traditional Chinese Medicine Attainable? [PDF]

, 2000
Julia Critchley, Zhang Ye, Chuthamanee Suthisisang, Thomas Y. K. Chan, Brian Tomlinson   +4 more
openalex   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source

Development of a Japanese version of the Fresno test for family physicians to measure evidence-based medicine competence. [PDF]

J Gen Fam Med
Kataoka Y, Maeno T, Kimura N, Ono Y, Suzuki M, Maeno T.   +5 more
europepmc   +1 more source

Artificial intelligence education: An evidence-based medicine approach for consumers, translators, and developers. [PDF]

Cell Rep Med, 2023
Ng FYC, Thirunavukarasu AJ, Cheng H, Tan TF, Gutierrez L, Lan Y, Ong JCL, Chong YS, Ngiam KY, Ho D, Wong TY, Kwek K, Doshi-Velez F, Lucey C, Coffman T, Ting DSW.   +15 more
europepmc   +1 more source

Evidence-based medicine

, 1999
Giuseppe Mancia, Alberto Zanchetti
openalex   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Digital health competences and AI beliefs as conditions for the practice of evidence-based medicine: a study of prospective physicians in Canada. [PDF]

Med Educ Online
Wagner G, Ringeval M, Raymond L, Paré G.   +3 more
europepmc   +1 more source

What Evidence-based Medicine (EBM) Doesn't Say About Allergen-specific Immunotherapy (AIT). [PDF]

Transl Med UniSa, 2023
Di Lorenzo G, Melluso M, Rodolico A.
europepmc   +1 more source

Patient perspective: Is intensive screening of women at high risk of breast cancer evidence-based medicine or déjà vu? [PDF]

Womens Health (Lond)
Fairman KA.
europepmc   +1 more source

Common misunderstandings of evidence-based medicine. [PDF]

Herzschrittmacherther Elektrophysiol, 2023
Semrau F, Aidelsburger P, Israel CW.
europepmc   +1 more source